Loading stock data…
$1.81+0.06 (+3.13%)
Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. in the Healthcare sector is trading at $1.81 with a market capitalization of $253M. Wall Street consensus targets $5.55 (10 analysts), implying a +205.8% move over the next 12 months. The stock is currently 30% below its 52-week high of $2.61, remaining 6.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$21.05M↓ | -$18.22M↓ | -$13.13M↑ | -$13.26M↓ | -$11.19M |
| Net Income | -$19.59M↓ | -$16.38M↓ | -$12.73M↓ | -$11.93M↓ | -$9.92M |
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threaten...